Paul Anthony Williams, Senior Vice President of Products Business at Emergent BioSolutions Inc., has executed a sale of 3,000 shares of the company's common stock. The transaction, which took place on July 1, 2026, resulted in a total value of $25,200. Each share was sold at a weighted average price of $8.40, with individual transaction prices ranging from $8.31 to $8.46. This sale was carried out pursuant to a pre-arranged trading plan established on November 14, 2025, designed to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934. Following the transaction, Williams retains direct ownership of 159,098 shares of Emergent BioSolutions common stock.
The stock currently trades at $8.16, which is slightly below the insider's sale price. The company's beta stands at 2.33, reflecting significant volatility in the market. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment and trades with a strong 32% free cash flow yield. The company earns a "GREAT" financial health score of 3.11.
In other recent news, Emergent BioSolutions reported first-quarter revenue for 2026 that exceeded expectations, reaching $156 million. This performance was primarily driven by the company's Medical Countermeasures segment and its naloxone franchise. Additionally, Emergent BioSolutions secured a $52.7 million contract modification from the Administration for Strategic Preparedness and Response to supply its ACAM2000 smallpox and mpox vaccine. The contract includes provisions for vaccine supplies, ancillaries, and diluent replacement lots, with deliveries set to begin this month. These developments highlight significant business activities for the company, reflecting its ongoing involvement in public health preparedness.